Loading…
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
Background: CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated. Methods: Within a prospective single-centre study serial blood samples were collected from patients with confirmed advanced PC. Pre-treatment valu...
Saved in:
| Published in: | British journal of cancer 2013-04, Vol.108 (8), p.1684-1694 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93 |
| container_end_page | 1694 |
| container_issue | 8 |
| container_start_page | 1684 |
| container_title | British journal of cancer |
| container_volume | 108 |
| creator | Boeck, S Wittwer, C Heinemann, V Haas, M Kern, C Stieber, P Nagel, D Holdenrieder, S |
| description | Background:
CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated.
Methods:
Within a prospective single-centre study serial blood samples were collected from patients with confirmed advanced PC. Pre-treatment values and weekly measurements of CYFRA 21-1, carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (assessed by Elecsys 2010, Roche Diagnostics) during palliative first-line chemotherapy were obtained. Biomarker data were correlated with objective response (determined by RECIST) as well as time to progression (TTP) and overall survival (OS) using uni- and multivariate analyses.
Results:
Seventy-eight patients were included, 45% of these received treatment in prospective clinical trials. Median TTP was 3.9 months, median OS 7.7 months. Pre-treatment CYFRA 21-1 levels were significantly associated with performance status (
P
=0.0399) and stage of disease (
P
=0.0001). Marker values before chemotherapy and at the 2-month staging of all three markers were considered significant predictors for objective treatment response. Pre-treatment CYFRA 21-1 levels, as well as CA 19-9 values, could be applied to define subgroups (categorised by tertiles) with a different OS outcome (CYFRA: 14.8
vs
7.1
vs
4.8 months, CA 19-9: 14.2
vs
7.1
vs
5.2 months;
P |
| doi_str_mv | 10.1038/bjc.2013.158 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3668481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2958610741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93</originalsourceid><addsrcrecordid>eNptkV9rFDEUxYNY7Lb65rMERFDorPkzk5l5EcpirVAQRB98CjeZzHbW2WSbzIz0C_Rze8fd1go-hdz7yzknHEJecrbkTFbvzcYuBeNyyYvqCVnwQoqMV6J8ShaMsTJjtWDH5CSlDV5rVpXPyLGQRVkLzhbkbnU7hJ8uwtB5yuusjbDeOj8k-nb14-LrORU84-8oJArUh8n1NLk4bqnpwhYiPqRtiDS6tAs-OQq-oWmMUzdBT1Fxh7p_1H51wzWFZgJvXYNjb6PDnaV2nsTn5KiFPrkXh_OUfL_4-G11mV19-fR5dX6V2bxiQ-agNI2VTDatqWph2pIpVkPTloqrQoCxOUiGUOFcCwUzykgrea1UUxbK1vKUfNjr7kazdY3FbBF6vYsd_uZWB-j0vxvfXet1mLRUqsorjgKvDwIx3IwuDXoTxugxs-YyLyUWkc_U2Z6yMaQUXfvgwJmeW9PYmp5b09ga4q8ep3qA72tC4M0BgGShx5K87dJfDn1FXs9ctucSrvzaxUfp_mf8GwXtsFw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1347301341</pqid></control><display><type>article</type><title>Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer</title><source>PubMed Central</source><creator>Boeck, S ; Wittwer, C ; Heinemann, V ; Haas, M ; Kern, C ; Stieber, P ; Nagel, D ; Holdenrieder, S</creator><creatorcontrib>Boeck, S ; Wittwer, C ; Heinemann, V ; Haas, M ; Kern, C ; Stieber, P ; Nagel, D ; Holdenrieder, S</creatorcontrib><description>Background:
CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated.
Methods:
Within a prospective single-centre study serial blood samples were collected from patients with confirmed advanced PC. Pre-treatment values and weekly measurements of CYFRA 21-1, carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (assessed by Elecsys 2010, Roche Diagnostics) during palliative first-line chemotherapy were obtained. Biomarker data were correlated with objective response (determined by RECIST) as well as time to progression (TTP) and overall survival (OS) using uni- and multivariate analyses.
Results:
Seventy-eight patients were included, 45% of these received treatment in prospective clinical trials. Median TTP was 3.9 months, median OS 7.7 months. Pre-treatment CYFRA 21-1 levels were significantly associated with performance status (
P
=0.0399) and stage of disease (
P
=0.0001). Marker values before chemotherapy and at the 2-month staging of all three markers were considered significant predictors for objective treatment response. Pre-treatment CYFRA 21-1 levels, as well as CA 19-9 values, could be applied to define subgroups (categorised by tertiles) with a different OS outcome (CYFRA: 14.8
vs
7.1
vs
4.8 months, CA 19-9: 14.2
vs
7.1
vs
5.2 months;
P
<0.0001). CYFRA 21-1 and CA 19-9 (both as categorised and as continuous variables) showed a highly significant correlation with TTP and OS at nearly all-time points assessed in univariate analysis. In multivariate analysis, only CYFRA 21-1 and performance status were independent predictors for OS.
Conclusions:
CYFRA 21-1 may serve as a valuable tool for monitoring treatment response and assessing prognosis in advanced PC.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2013.158</identifier><identifier>PMID: 23579210</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[692/699/67/1504/1713 ; 692/699/67/1857 ; 692/700/1750 ; 692/700/565/1436/99 ; Adult ; Aged ; Albumins - therapeutic use ; Antigens, Neoplasm - blood ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Axitinib ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; CA-19-9 Antigen - blood ; Cancer Research ; Capecitabine ; Carcinoembryonic Antigen - blood ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Disease-Free Survival ; Drug Resistance ; Epidemiology ; Erlotinib Hydrochloride ; Everolimus ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Fluorouracil - therapeutic use ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Imidazoles - administration & dosage ; Indazoles - administration & dosage ; Keratin-19 - blood ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Middle Aged ; Molecular Diagnostics ; Molecular Medicine ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Multivariate Analysis ; Oncology ; Paclitaxel - therapeutic use ; Palliative Care ; Pancreatic cancer ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - drug therapy ; Piperazines - administration & dosage ; Prospective Studies ; Quinazolines - administration & dosage ; Sirolimus - administration & dosage ; Sirolimus - analogs & derivatives ; Sulfonamides - administration & dosage ; Survival Rate ; Tumors]]></subject><ispartof>British journal of cancer, 2013-04, Vol.108 (8), p.1684-1694</ispartof><rights>The Author(s) 2013</rights><rights>2014 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 30, 2013</rights><rights>Copyright © 2013 Cancer Research UK 2013 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93</citedby><cites>FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668481/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668481/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27302490$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23579210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boeck, S</creatorcontrib><creatorcontrib>Wittwer, C</creatorcontrib><creatorcontrib>Heinemann, V</creatorcontrib><creatorcontrib>Haas, M</creatorcontrib><creatorcontrib>Kern, C</creatorcontrib><creatorcontrib>Stieber, P</creatorcontrib><creatorcontrib>Nagel, D</creatorcontrib><creatorcontrib>Holdenrieder, S</creatorcontrib><title>Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated.
Methods:
Within a prospective single-centre study serial blood samples were collected from patients with confirmed advanced PC. Pre-treatment values and weekly measurements of CYFRA 21-1, carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (assessed by Elecsys 2010, Roche Diagnostics) during palliative first-line chemotherapy were obtained. Biomarker data were correlated with objective response (determined by RECIST) as well as time to progression (TTP) and overall survival (OS) using uni- and multivariate analyses.
Results:
Seventy-eight patients were included, 45% of these received treatment in prospective clinical trials. Median TTP was 3.9 months, median OS 7.7 months. Pre-treatment CYFRA 21-1 levels were significantly associated with performance status (
P
=0.0399) and stage of disease (
P
=0.0001). Marker values before chemotherapy and at the 2-month staging of all three markers were considered significant predictors for objective treatment response. Pre-treatment CYFRA 21-1 levels, as well as CA 19-9 values, could be applied to define subgroups (categorised by tertiles) with a different OS outcome (CYFRA: 14.8
vs
7.1
vs
4.8 months, CA 19-9: 14.2
vs
7.1
vs
5.2 months;
P
<0.0001). CYFRA 21-1 and CA 19-9 (both as categorised and as continuous variables) showed a highly significant correlation with TTP and OS at nearly all-time points assessed in univariate analysis. In multivariate analysis, only CYFRA 21-1 and performance status were independent predictors for OS.
Conclusions:
CYFRA 21-1 may serve as a valuable tool for monitoring treatment response and assessing prognosis in advanced PC.</description><subject>692/699/67/1504/1713</subject><subject>692/699/67/1857</subject><subject>692/700/1750</subject><subject>692/700/565/1436/99</subject><subject>Adult</subject><subject>Aged</subject><subject>Albumins - therapeutic use</subject><subject>Antigens, Neoplasm - blood</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Axitinib</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>CA-19-9 Antigen - blood</subject><subject>Cancer Research</subject><subject>Capecitabine</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Erlotinib Hydrochloride</subject><subject>Everolimus</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Imidazoles - administration & dosage</subject><subject>Indazoles - administration & dosage</subject><subject>Keratin-19 - blood</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Paclitaxel - therapeutic use</subject><subject>Palliative Care</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Piperazines - administration & dosage</subject><subject>Prospective Studies</subject><subject>Quinazolines - administration & dosage</subject><subject>Sirolimus - administration & dosage</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sulfonamides - administration & dosage</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNptkV9rFDEUxYNY7Lb65rMERFDorPkzk5l5EcpirVAQRB98CjeZzHbW2WSbzIz0C_Rze8fd1go-hdz7yzknHEJecrbkTFbvzcYuBeNyyYvqCVnwQoqMV6J8ShaMsTJjtWDH5CSlDV5rVpXPyLGQRVkLzhbkbnU7hJ8uwtB5yuusjbDeOj8k-nb14-LrORU84-8oJArUh8n1NLk4bqnpwhYiPqRtiDS6tAs-OQq-oWmMUzdBT1Fxh7p_1H51wzWFZgJvXYNjb6PDnaV2nsTn5KiFPrkXh_OUfL_4-G11mV19-fR5dX6V2bxiQ-agNI2VTDatqWph2pIpVkPTloqrQoCxOUiGUOFcCwUzykgrea1UUxbK1vKUfNjr7kazdY3FbBF6vYsd_uZWB-j0vxvfXet1mLRUqsorjgKvDwIx3IwuDXoTxugxs-YyLyUWkc_U2Z6yMaQUXfvgwJmeW9PYmp5b09ga4q8ep3qA72tC4M0BgGShx5K87dJfDn1FXs9ctucSrvzaxUfp_mf8GwXtsFw</recordid><startdate>20130430</startdate><enddate>20130430</enddate><creator>Boeck, S</creator><creator>Wittwer, C</creator><creator>Heinemann, V</creator><creator>Haas, M</creator><creator>Kern, C</creator><creator>Stieber, P</creator><creator>Nagel, D</creator><creator>Holdenrieder, S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20130430</creationdate><title>Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer</title><author>Boeck, S ; Wittwer, C ; Heinemann, V ; Haas, M ; Kern, C ; Stieber, P ; Nagel, D ; Holdenrieder, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>692/699/67/1504/1713</topic><topic>692/699/67/1857</topic><topic>692/700/1750</topic><topic>692/700/565/1436/99</topic><topic>Adult</topic><topic>Aged</topic><topic>Albumins - therapeutic use</topic><topic>Antigens, Neoplasm - blood</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Axitinib</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>CA-19-9 Antigen - blood</topic><topic>Cancer Research</topic><topic>Capecitabine</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Erlotinib Hydrochloride</topic><topic>Everolimus</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Imidazoles - administration & dosage</topic><topic>Indazoles - administration & dosage</topic><topic>Keratin-19 - blood</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Paclitaxel - therapeutic use</topic><topic>Palliative Care</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Piperazines - administration & dosage</topic><topic>Prospective Studies</topic><topic>Quinazolines - administration & dosage</topic><topic>Sirolimus - administration & dosage</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sulfonamides - administration & dosage</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boeck, S</creatorcontrib><creatorcontrib>Wittwer, C</creatorcontrib><creatorcontrib>Heinemann, V</creatorcontrib><creatorcontrib>Haas, M</creatorcontrib><creatorcontrib>Kern, C</creatorcontrib><creatorcontrib>Stieber, P</creatorcontrib><creatorcontrib>Nagel, D</creatorcontrib><creatorcontrib>Holdenrieder, S</creatorcontrib><collection>SpringerOpen</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boeck, S</au><au>Wittwer, C</au><au>Heinemann, V</au><au>Haas, M</au><au>Kern, C</au><au>Stieber, P</au><au>Nagel, D</au><au>Holdenrieder, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2013-04-30</date><risdate>2013</risdate><volume>108</volume><issue>8</issue><spage>1684</spage><epage>1694</epage><pages>1684-1694</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated.
Methods:
Within a prospective single-centre study serial blood samples were collected from patients with confirmed advanced PC. Pre-treatment values and weekly measurements of CYFRA 21-1, carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (assessed by Elecsys 2010, Roche Diagnostics) during palliative first-line chemotherapy were obtained. Biomarker data were correlated with objective response (determined by RECIST) as well as time to progression (TTP) and overall survival (OS) using uni- and multivariate analyses.
Results:
Seventy-eight patients were included, 45% of these received treatment in prospective clinical trials. Median TTP was 3.9 months, median OS 7.7 months. Pre-treatment CYFRA 21-1 levels were significantly associated with performance status (
P
=0.0399) and stage of disease (
P
=0.0001). Marker values before chemotherapy and at the 2-month staging of all three markers were considered significant predictors for objective treatment response. Pre-treatment CYFRA 21-1 levels, as well as CA 19-9 values, could be applied to define subgroups (categorised by tertiles) with a different OS outcome (CYFRA: 14.8
vs
7.1
vs
4.8 months, CA 19-9: 14.2
vs
7.1
vs
5.2 months;
P
<0.0001). CYFRA 21-1 and CA 19-9 (both as categorised and as continuous variables) showed a highly significant correlation with TTP and OS at nearly all-time points assessed in univariate analysis. In multivariate analysis, only CYFRA 21-1 and performance status were independent predictors for OS.
Conclusions:
CYFRA 21-1 may serve as a valuable tool for monitoring treatment response and assessing prognosis in advanced PC.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23579210</pmid><doi>10.1038/bjc.2013.158</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2013-04, Vol.108 (8), p.1684-1694 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3668481 |
| source | PubMed Central |
| subjects | 692/699/67/1504/1713 692/699/67/1857 692/700/1750 692/700/565/1436/99 Adult Aged Albumins - therapeutic use Antigens, Neoplasm - blood Antineoplastic Combined Chemotherapy Protocols - therapeutic use Axitinib Biological and medical sciences Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine CA-19-9 Antigen - blood Cancer Research Capecitabine Carcinoembryonic Antigen - blood Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Disease-Free Survival Drug Resistance Epidemiology Erlotinib Hydrochloride Everolimus Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Gastroenterology. Liver. Pancreas. Abdomen Humans Imidazoles - administration & dosage Indazoles - administration & dosage Keratin-19 - blood Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Middle Aged Molecular Diagnostics Molecular Medicine Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Multivariate Analysis Oncology Paclitaxel - therapeutic use Palliative Care Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - drug therapy Piperazines - administration & dosage Prospective Studies Quinazolines - administration & dosage Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sulfonamides - administration & dosage Survival Rate Tumors |
| title | Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T14%3A13%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytokeratin%2019-fragments%20(CYFRA%2021-1)%20as%20a%20novel%20serum%20biomarker%20for%20response%20and%20survival%20in%20patients%20with%20advanced%20pancreatic%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Boeck,%20S&rft.date=2013-04-30&rft.volume=108&rft.issue=8&rft.spage=1684&rft.epage=1694&rft.pages=1684-1694&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2013.158&rft_dat=%3Cproquest_pubme%3E2958610741%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c480t-ea7bdc303dfb892bf70609adf761652abc4a30a7b5eefa50b6b3c31966d756c93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1347301341&rft_id=info:pmid/23579210&rfr_iscdi=true |